Liangping Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liangping Li has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Chanchan Song
Institute of Clinical Oncology, Research Center of Cancer Diagnosis and Therapy, and Department of Clinical Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China
4 shared publicationsXianlin Yuan
Department of Clinical Oncology, Research Center of Cancer Diagnosis and Therapy, Institute of Clinical Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China
3 shared publicationsBaoyi Liao
Institute of Clinical Oncology, Research Center of Cancer Diagnosis and Therapy, and Department of Clinical Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China
2 shared publicationsHaishan Li
Clinical Laboratory, Zhongshan Boai Hospital, Zhongshan, China
2 shared publicationsJia Yuan
Department of Clinical Oncology, Research Center of Cancer Diagnosis and Therapy, Institute of Clinical Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China
2 shared publicationsJunxia Gao
Department of Clinical Oncology, Research Center of Cancer Diagnosis and Therapy, Institute of Clinical Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Analysis of the tumor reactivity of autologous TILs and allogeneic γδ T cells via tumor organoid–immune cell coculture
Background: The efficacy of conventional αβ T cell-based immunotherapies is often limited by tumor immune evasion. γδ T cells can bypass these limitations through MHC-independent tumor recognition, but their function within the tumor microenvironment (TME) remains poorly characterized due to a lack of relevant preclinical models. This study aims to establish a patient-derived tumor organoid-immune cell coculture system to evaluate γδ T-cell reactivity and cytotoxicity in a human-relevant TME ( n = 10 PDTO lines; n = 3 independent experiments). Methods: We developed an innovative coculture system—believed to be the first to integrate patient-derived tumor organoids (PDTOs) and autologous tumor-infiltrating lymphocytes (TILs) or healthy donor-derived allogeneic Vγ9Vδ2 T cell. T-cell activation was quantified by comparing CD137 expression on γδ T cells versus CD4 + and CD8 + T cells via flow cytometry after coculture. The cytotoxicity of Vγ9Vδ2 T cells was evaluated at various effector-to-target (E:T) ratios using a live-cell imaging assay to track BCO infiltration and apoptosis over 24 hours. Secreted effector molecules (IFN-γ, granzyme B, perforin) were measured from coculture supernatants using a cytometric bead array. Results: Baseline analysis revealed that γδ T cells represent the most reactive subset within expanded TILs, with 12.3% expressing CD137 compared to 3.49% of CD8 + T cells ( p = 0.0118). Notably, autologous BCO–TIL coculture preferentially enhanced γδ T-cell activation, reaching 24.85% CD137 + —a frequency significantly higher than that of CD8 (9.15%, p = 0.0062) and CD4 (9.99%) subsets. The net increase in CD137 positivity for γδ T cells was more than double that of CD8 T cells (12.55% vs. 5.66%, p = 0.0467). Allogeneic Vγ9Vδ2 T cells demonstrated significant, dose-dependent cytotoxicity against BCOs ( p < 0.0001). Maximal cell death (RFU fold-change: 5.2 ± 0.5) was achieved at an effector-to-target (E:T) ratio of 10:1 ( p < 0.0001). This cytotoxic efficacy was highly correlated with the secretion of lytic effectors, including IFN-γ ( > 1000 pg/mL; p < 0.001), granzyme B ( > 2000 pg/mL), and perforin ( > 350 pg/mL). Conclusion: Our findings demonstrate that 3D autologous coculture leads to the preferential stimulation of γδ T cells, establishing them as a primary reactive subset capable of bypassing MHC-restriction bottlenecks. The potent dismantling of tumor architecture by allogeneic Vγ9Vδ2 T cells, supported by high-resolution kinetic and cytokine data, substantiates their development as “off-the-shelf” therapies. Collectively, this platform provides a standardized, high-fidelity engine for the rapid preclinical assessment of next-generation cellular immunotherapies.
- 25 April 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessAnalysis of the tumor reactivity of autologous TILs and allogeneic γδ T cells via tumor organoid–immune cell coculture
Background: The efficacy of conventional αβ T cell-based immunotherapies is often limited by tumor immune evasion. γδ T cells can bypass these limitations through MHC-independent tumor recognition, but their function within the tumor microenvironment (TME) remains poorly characterized due to a lack of relevant preclinical models. This study aims to establish a patient-derived tumor organoid-immune cell coculture system to evaluate γδ T-cell reactivity and cytotoxicity in a human-relevant TME ( n = 10 PDTO lines; n = 3 independent experiments). Methods: We developed an innovative coculture system—believed to be the first to integrate patient-derived tumor organoids (PDTOs) and autologous tumor-infiltrating lymphocytes (TILs) or healthy donor-derived allogeneic Vγ9Vδ2 T cell. T-cell activation was quantified by comparing CD137 expression on γδ T cells versus CD4 + and CD8 + T cells via flow cytometry after coculture. The cytotoxicity of Vγ9Vδ2 T cells was evaluated at various effector-to-target (E:T) ratios using a live-cell imaging assay to track BCO infiltration and apoptosis over 24 hours. Secreted effector molecules (IFN-γ, granzyme B, perforin) were measured from coculture supernatants using a cytometric bead array. Results: Baseline analysis revealed that γδ T cells represent the most reactive subset within expanded TILs, with 12.3% expressing CD137 compared to 3.49% of CD8 + T cells ( p = 0.0118). Notably, autologous BCO–TIL coculture preferentially enhanced γδ T-cell activation, reaching 24.85% CD137 + —a frequency significantly higher than that of CD8 (9.15%, p = 0.0062) and CD4 (9.99%) subsets. The net increase in CD137 positivity for γδ T cells was more than double that of CD8 T cells (12.55% vs. 5.66%, p = 0.0467). Allogeneic Vγ9Vδ2 T cells demonstrated significant, dose-dependent cytotoxicity against BCOs ( p < 0.0001). Maximal cell death (RFU fold-change: 5.2 ± 0.5) was achieved at an effector-to-target (E:T) ratio of 10:1 ( p < 0.0001). This cytotoxic efficacy was highly correlated with the secretion of lytic effectors, including IFN-γ ( > 1000 pg/mL; p < 0.001), granzyme B ( > 2000 pg/mL), and perforin ( > 350 pg/mL). Conclusion: Our findings demonstrate that 3D autologous coculture leads to the preferential stimulation of γδ T cells, establishing them as a primary reactive subset capable of bypassing MHC-restriction bottlenecks. The potent dismantling of tumor architecture by allogeneic Vγ9Vδ2 T cells, supported by high-resolution kinetic and cytokine data, substantiates their development as “off-the-shelf” therapies. Collectively, this platform provides a standardized, high-fidelity engine for the rapid preclinical assessment of next-generation cellular immunotherapies.
- Open Access
- 12 August 2025
- Published by Springer Nature in Research Square
Detecting Tumor Reactivity of Autologous and Allogeneic γδ T Cells via Tumor Organoid-Immune Cells Co-Culture
Background: Cancer immunotherapies primarily target conventional αβ T cells, yet their clinical effectiveness is frequently undermined by immune evasion mechanisms inherent to tumors. γδ T cells, a distinct class of unconventional lymphocytes, recognize tumor-associated antigens independently of MHC molecules, potentially overcoming these limitations. However, comprehensive evaluations of γδ T cell functionality within the tumor microenvironment (TME) remain scarce. Methods: We developed an innovative patient-derived tumor organoid (PDTO) and immune cell co-culture platform, integrating autologous tumor-infiltrating lymphocytes (TILs) and healthy donor-derived allogeneic Vγ9Vδ2 T cells. Utilizing fluorescent cell-tracing, multiplex cytokine analyses, and flow cytometry, we assessed γδ T cell infiltration, activation, and cytotoxicity within breast cancer organoids, closely mimicking physiological tumor conditions. Results: Our findings reveal that autologous γδ T cells demonstrate significantly enhanced tumor-specific activation compared to conventional αβ T cell subsets, as indicated by elevated CD137 expression. Additionally, allogeneic Vγ9Vδ2 T cells exhibited robust cytotoxic activity against breast cancer organoids, with cytotoxic efficacy correlating with higher effector-to-target ratios and increased secretion of IFN-γ, granzyme B, and perforin. Conclusion: The established PDTO–immune cell co-culture platform provides a physiologically relevant model for evaluating γδ T cell reactivity and cytotoxicity. These results underscore the potential of γδ T cells as effective candidates for cancer immunotherapy, offering significant promise for developing novel therapeutic strategies against solid tumors.
- 12 August 2025
- Published by Springer Nature in Research Square
Open AccessDetecting Tumor Reactivity of Autologous and Allogeneic γδ T Cells via Tumor Organoid-Immune Cells Co-Culture
Background: Cancer immunotherapies primarily target conventional αβ T cells, yet their clinical effectiveness is frequently undermined by immune evasion mechanisms inherent to tumors. γδ T cells, a distinct class of unconventional lymphocytes, recognize tumor-associated antigens independently of MHC molecules, potentially overcoming these limitations. However, comprehensive evaluations of γδ T cell functionality within the tumor microenvironment (TME) remain scarce. Methods: We developed an innovative patient-derived tumor organoid (PDTO) and immune cell co-culture platform, integrating autologous tumor-infiltrating lymphocytes (TILs) and healthy donor-derived allogeneic Vγ9Vδ2 T cells. Utilizing fluorescent cell-tracing, multiplex cytokine analyses, and flow cytometry, we assessed γδ T cell infiltration, activation, and cytotoxicity within breast cancer organoids, closely mimicking physiological tumor conditions. Results: Our findings reveal that autologous γδ T cells demonstrate significantly enhanced tumor-specific activation compared to conventional αβ T cell subsets, as indicated by elevated CD137 expression. Additionally, allogeneic Vγ9Vδ2 T cells exhibited robust cytotoxic activity against breast cancer organoids, with cytotoxic efficacy correlating with higher effector-to-target ratios and increased secretion of IFN-γ, granzyme B, and perforin. Conclusion: The established PDTO–immune cell co-culture platform provides a physiologically relevant model for evaluating γδ T cell reactivity and cytotoxicity. These results underscore the potential of γδ T cells as effective candidates for cancer immunotherapy, offering significant promise for developing novel therapeutic strategies against solid tumors.
- Open Access
- 7 July 2022
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (7) , e004713
Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Background: T-cell receptor-engineered T cells (TCR-Ts) have achieved encouraging success in anticancer clinical trials. The antigenic targets, however, were primarily focused on human leukocyte antigen (HLA) A*02:01 restricted epitopes from a few cancer/testis antigens (CTAs) which are not widely expressed in common solid cancers; the tested T-cell receptors (TCRs) were frequently from tumor-infiltrating lymphocytes of old patients and were not assured to have higher avidity. Here, we propose the isolation of high-avidity TCRs against CTAs that are frequently expressed in common solid cancers. Methods: We selected the CT83 protein, which is frequently expressed in common solid cancers, as a model antigen for screening of its specific TCR. The predicted CT83 epitopes with strong or weak binding to HLA-I molecules, popular in the Chinese population, were integrated into three synthetic long peptides. CT83 reactive CD8+ T cells were stimulated with peptide-loaded dendritic cells (DCs) and sorted using the CD137 biomarker for single-cell sequencing to obtain the paired TCRαβ sequence. The higher frequency TCRs were reconstructed for characterization of the CT83 epitope and for assessment of in vitro and in vivo antitumor activities. Results: CT83 reactive T cells from young healthy donors (YHDs) were generated by repeated stimulation with DCs and peptides. The single-cell TCR sequencing results of reactive T cells indicated that a single TCR clonotype dominated the paired TCRs. T cells engineered with this dominant TCR led to HLA-A*11:01-restricted recognition of the CT8314-22 epitope, with higher avidity. Functional assays showed powerful cytotoxicity in vitro against the targets of several CT83-positive solid cancer cell lines. Furthermore, TCR-Ts showed therapeutic efficacy in three xenograft solid tumor models. The meta-analysis of gene expression of 92 CTAs indicated that most CTAs did not or at low levels in the thymus, which suggested that those CTAs may experience incomplete thymic central tolerance. Conclusions: High-avidity TCR against CT83 could be isolated from YHDs and efficiently mediate regression of well-established xenograft common solid tumors. The high-avidity TCR repertoire in the peripheral blood of some donors for CT83 and other CTAs provides the basis for the efficient isolation of high-avidity TCRs to target numerous solid cancers.
- 7 July 2022
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (7) , e004713
Open AccessNatural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Background: T-cell receptor-engineered T cells (TCR-Ts) have achieved encouraging success in anticancer clinical trials. The antigenic targets, however, were primarily focused on human leukocyte antigen (HLA) A*02:01 restricted epitopes from a few cancer/testis antigens (CTAs) which are not widely expressed in common solid cancers; the tested T-cell receptors (TCRs) were frequently from tumor-infiltrating lymphocytes of old patients and were not assured to have higher avidity. Here, we propose the isolation of high-avidity TCRs against CTAs that are frequently expressed in common solid cancers. Methods: We selected the CT83 protein, which is frequently expressed in common solid cancers, as a model antigen for screening of its specific TCR. The predicted CT83 epitopes with strong or weak binding to HLA-I molecules, popular in the Chinese population, were integrated into three synthetic long peptides. CT83 reactive CD8+ T cells were stimulated with peptide-loaded dendritic cells (DCs) and sorted using the CD137 biomarker for single-cell sequencing to obtain the paired TCRαβ sequence. The higher frequency TCRs were reconstructed for characterization of the CT83 epitope and for assessment of in vitro and in vivo antitumor activities. Results: CT83 reactive T cells from young healthy donors (YHDs) were generated by repeated stimulation with DCs and peptides. The single-cell TCR sequencing results of reactive T cells indicated that a single TCR clonotype dominated the paired TCRs. T cells engineered with this dominant TCR led to HLA-A*11:01-restricted recognition of the CT8314-22 epitope, with higher avidity. Functional assays showed powerful cytotoxicity in vitro against the targets of several CT83-positive solid cancer cell lines. Furthermore, TCR-Ts showed therapeutic efficacy in three xenograft solid tumor models. The meta-analysis of gene expression of 92 CTAs indicated that most CTAs did not or at low levels in the thymus, which suggested that those CTAs may experience incomplete thymic central tolerance. Conclusions: High-avidity TCR against CT83 could be isolated from YHDs and efficiently mediate regression of well-established xenograft common solid tumors. The high-avidity TCR repertoire in the peripheral blood of some donors for CT83 and other CTAs provides the basis for the efficient isolation of high-avidity TCRs to target numerous solid cancers.
- Open Access
- 28 February 2022
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1
Correction to: Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells
- 28 February 2022
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1
Open AccessCorrection to: Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells
- Open Access
- 2 February 2022
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1-17
Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells
Background: Endothelial cells (ECs) derived from human-induced pluripotent stem cell (iPSC) are a valuable cell resource for cardiovascular regeneration. To avoid time-consuming preparation from primary autologous cells, the allogeneic iPSC-ECs are being expected to become “off-the-shelf” cell products. However, allorejection caused by HLA mismatching is a major barrier for this strategy. Although the “hypoimmunogenic” iPSCs could be simply generated by inhibition of HLA-I expression via β-2 microglobulin knockout (B2M KO), the deletion of HLA-I expression will activate natural killer (NK) cells, which kill the HLA-I negative cells. To inhibit NK activation, we proposed to generate HLA-matched iPSCs based on patient’s HLA genotyping by HLA exchanging approach to express the required HLA allele. Methods: To establish a prototype of HLA exchanging system, the expression of HLA-I molecules of iPSCs was inhibited by CRISPR/Cas9-mediated B2M KO, and then HLA-A*11:01 allele, as a model molecule, was introduced into B2M KO iPSCs by lentiviral gene transfer. HLA-I-modified iPSCs were tested for their pluripotency and ability to differentiate into ECs. The stimulation of iPSC-EC to allogeneic T and NK cells was detected by respective co-culture of PBMC-EC and NK-EC. Finally, the iPSC-ECs were used as the seeding cells to re-endothelialize the decellularized valves. Results: We generated the iPSCs only expressed one HLA-A allele (HLA-A *11:01) by B2M KO plus HLA gene transfer. These HLA-I-modified iPSCs maintained pluripotency and furthermore were successfully differentiated into functional ECs assessed by tube formation assay. Single HLA-A*11:01-matched iPSC-ECs significantly less induced the allogeneic response of CD8+ T cell and NK cells expressing matched HLA-A*11:01 and other HLA-A,-B and -C alleles. These cells were successfully used to re-endothelialize the decellularized valves. Conclusions: In summary, a simple HLA-I exchanging system has been created by efficient HLA engineering of iPSCs to evade both of the alloresponse of CD8+ T cells and the activation of NK cells. This technology has been applied to generate iPSC-ECs for the engineering of cellular heart valves. Our strategy should be extremely useful if the “off-the-shelf” and “non-immunogenic” allogeneic iPSCs were created for the common HLA alleles.
- 2 February 2022
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1-17
Open AccessGeneration of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells
Background: Endothelial cells (ECs) derived from human-induced pluripotent stem cell (iPSC) are a valuable cell resource for cardiovascular regeneration. To avoid time-consuming preparation from primary autologous cells, the allogeneic iPSC-ECs are being expected to become “off-the-shelf” cell products. However, allorejection caused by HLA mismatching is a major barrier for this strategy. Although the “hypoimmunogenic” iPSCs could be simply generated by inhibition of HLA-I expression via β-2 microglobulin knockout (B2M KO), the deletion of HLA-I expression will activate natural killer (NK) cells, which kill the HLA-I negative cells. To inhibit NK activation, we proposed to generate HLA-matched iPSCs based on patient’s HLA genotyping by HLA exchanging approach to express the required HLA allele. Methods: To establish a prototype of HLA exchanging system, the expression of HLA-I molecules of iPSCs was inhibited by CRISPR/Cas9-mediated B2M KO, and then HLA-A*11:01 allele, as a model molecule, was introduced into B2M KO iPSCs by lentiviral gene transfer. HLA-I-modified iPSCs were tested for their pluripotency and ability to differentiate into ECs. The stimulation of iPSC-EC to allogeneic T and NK cells was detected by respective co-culture of PBMC-EC and NK-EC. Finally, the iPSC-ECs were used as the seeding cells to re-endothelialize the decellularized valves. Results: We generated the iPSCs only expressed one HLA-A allele (HLA-A *11:01) by B2M KO plus HLA gene transfer. These HLA-I-modified iPSCs maintained pluripotency and furthermore were successfully differentiated into functional ECs assessed by tube formation assay. Single HLA-A*11:01-matched iPSC-ECs significantly less induced the allogeneic response of CD8+ T cell and NK cells expressing matched HLA-A*11:01 and other HLA-A,-B and -C alleles. These cells were successfully used to re-endothelialize the decellularized valves. Conclusions: In summary, a simple HLA-I exchanging system has been created by efficient HLA engineering of iPSCs to evade both of the alloresponse of CD8+ T cells and the activation of NK cells. This technology has been applied to generate iPSC-ECs for the engineering of cellular heart valves. Our strategy should be extremely useful if the “off-the-shelf” and “non-immunogenic” allogeneic iPSCs were created for the common HLA alleles.
- 14 April 2021
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (11) , 3291-3302
Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens
Cancer immunotherapies, including immune checkpoint blockage and adoptive transfer of CAR-T cells, have achieved historical successes for many kinds of malignancy. However, a minority of patients survive long term over 5 years without relapse, perhaps owing to tumor heterogeneity and potent immunosuppression in the tumor microenvironment. Here, using an established mouse tumor model of triple-negative 4T1 breast cancer, we show that local immunochemotherapy triggers powerful local and systemic antitumor immunity. Paraneoplastic injection of CpG, α-OX40, and anthracycline completely eliminated both local and distant large established 4T1 breast cancer without obvious relapse. Analysis of the immune cells at tumor tissues, draining lymph nodes, and spleens revealed that the local treatment increased the infiltration of CD4+ and CD8+ T cells in all three tissues and inhibited the accumulation of myeloid-derived suppressor cells in the spleen in a delayed response. Most importantly, this treatment triggered systemic T cell response against 4T1 tumors and some of their neoantigen epitopes as detected by IFN-γ ELISpot and intracellular cytokine assays in splenocytes. Furthermore, T cells showed specific cytotoxic activity against 4T1 tumor cells in vitro. In general, this local immunochemotherapy provides a new approach to target highly diverse neoantigens in various types of cancers without complicated and expensive antigen identification via next-generation sequencing.
- 14 April 2021
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (11) , 3291-3302
Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens
Cancer immunotherapies, including immune checkpoint blockage and adoptive transfer of CAR-T cells, have achieved historical successes for many kinds of malignancy. However, a minority of patients survive long term over 5 years without relapse, perhaps owing to tumor heterogeneity and potent immunosuppression in the tumor microenvironment. Here, using an established mouse tumor model of triple-negative 4T1 breast cancer, we show that local immunochemotherapy triggers powerful local and systemic antitumor immunity. Paraneoplastic injection of CpG, α-OX40, and anthracycline completely eliminated both local and distant large established 4T1 breast cancer without obvious relapse. Analysis of the immune cells at tumor tissues, draining lymph nodes, and spleens revealed that the local treatment increased the infiltration of CD4+ and CD8+ T cells in all three tissues and inhibited the accumulation of myeloid-derived suppressor cells in the spleen in a delayed response. Most importantly, this treatment triggered systemic T cell response against 4T1 tumors and some of their neoantigen epitopes as detected by IFN-γ ELISpot and intracellular cytokine assays in splenocytes. Furthermore, T cells showed specific cytotoxic activity against 4T1 tumor cells in vitro. In general, this local immunochemotherapy provides a new approach to target highly diverse neoantigens in various types of cancers without complicated and expensive antigen identification via next-generation sequencing.
- Open Access
- 30 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
A Local and Low-Dose Chemotherapy/Autophagy-Enhancing Regimen Treatment Markedly Inhibited the Growth of Established Solid Tumors Through a Systemic Antitumor Immune Response
Chemotherapy is one of the main options for the treatment of a variety of malignant tumors. However, the severe side effects resulting from the killing of normal proliferating cells limit the application of cancer-targeting chemotherapeutic drugs. To improve the efficacy of classic systemic chemotherapy, the local delivery of high-dose chemotherapeutic drugs was developed as a method to enhance local drug concentrations and minimize systemic toxicity. Studies have demonstrated that chemotherapy is often accompanied by cancer-associated immunogenic cell death (ICD) and that autophagy is involved in the induction of ICD. To improve the efficacy of local cancer chemotherapy, we hypothesized that the local delivery of chemotherapeutic plus autophagy-enhancing agents would enhance the promotive effects of ICD on the antitumor immune response. Here, we report that a low-dose chemotherapy/autophagy enhancing regimen (CAER) not only resulted in the increased death of B16F10 and 4T1 tumor cells, but also induced higher levels of autophagy in vitro. Importantly, the local delivery of the CARE drugs significantly inhibited tumor growth in B16F10 and 4T1 tumor-bearing mice. Systemic antitumor T-cell immunity was observed in vivo, including neoantigen-specific T-cell responses. Furthermore, bioinformatic analysis of human breast cancer and melanoma tissues showed that autophagy-associated gene expression was upregulated in tumor samples. Increased autophagy and immune cell infiltration in tumor tissues were positively correlated with good prognosis of tumor patients. This work highlights a new approach to improve the effects of local chemotherapy and enhance systemic antitumor immunity.
- 30 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessA Local and Low-Dose Chemotherapy/Autophagy-Enhancing Regimen Treatment Markedly Inhibited the Growth of Established Solid Tumors Through a Systemic Antitumor Immune Response
Chemotherapy is one of the main options for the treatment of a variety of malignant tumors. However, the severe side effects resulting from the killing of normal proliferating cells limit the application of cancer-targeting chemotherapeutic drugs. To improve the efficacy of classic systemic chemotherapy, the local delivery of high-dose chemotherapeutic drugs was developed as a method to enhance local drug concentrations and minimize systemic toxicity. Studies have demonstrated that chemotherapy is often accompanied by cancer-associated immunogenic cell death (ICD) and that autophagy is involved in the induction of ICD. To improve the efficacy of local cancer chemotherapy, we hypothesized that the local delivery of chemotherapeutic plus autophagy-enhancing agents would enhance the promotive effects of ICD on the antitumor immune response. Here, we report that a low-dose chemotherapy/autophagy enhancing regimen (CAER) not only resulted in the increased death of B16F10 and 4T1 tumor cells, but also induced higher levels of autophagy in vitro. Importantly, the local delivery of the CARE drugs significantly inhibited tumor growth in B16F10 and 4T1 tumor-bearing mice. Systemic antitumor T-cell immunity was observed in vivo, including neoantigen-specific T-cell responses. Furthermore, bioinformatic analysis of human breast cancer and melanoma tissues showed that autophagy-associated gene expression was upregulated in tumor samples. Increased autophagy and immune cell infiltration in tumor tissues were positively correlated with good prognosis of tumor patients. This work highlights a new approach to improve the effects of local chemotherapy and enhance systemic antitumor immunity.
- Open Access
The influence of major S protein mutations of SARS-CoV-2 on the potential B cell epitopes
SARS-CoV-2 has rapidly transmitted worldwide and results in the COVID-19 pandemic. Spike glycoprotein on surface is a key factor of viral transmission, and has appeared a lot of variants due to gene mutations, which may influence the viral antigenicity and vaccine efficacy. Here, we used bioinformatic tools to analyze B-cell epitopes of prototype S protein and its 9 common variants. 12 potential linear and 53 discontinuous epitopes of B-cells were predicted from the S protein prototype. Importantly, by comparing the epitope alterations between prototype and variants, we demonstrate that B-cell epitopes and antigenicity of 9 variants appear significantly different alterations. The dominant D614G variant impacts the potential epitope least, only with moderately elevated antigenicity, while the epitopes and antigenicity of some mutants(V483A, V367F, etc.) with small incidence in the population change greatly. These results suggest that the currently developed vaccines should be valid for a majority of SARS-CoV-2 infectors. This study provides a scientific basis for large-scale application of SARS-CoV-2 vaccines and for taking precautions against the probable appearance of antigen escape induced by genetic variation after vaccination. Author Summary: The global pandemic of SARS-CoV-2 has lasted for more than half a year and has not yet been contained. Until now there is no effective treatment for SARS-CoV-2 caused disease (COVID-19). Successful vaccine development seems to be the only hope. However, this novel coronavirus belongs to the RNA virus, there is a high mutation rate in the genome, and these mutations often locate on the Spike proteins of virus, the gripper of the virus entering the cells. Vaccination induce the generation of antibodies, which block Spike protein. However, the Spike protein variants may change the recognition and binding of antibodies and make the vaccine ineffective. In this study, we predict neutralizing antibody recognition sites (B cell epitopes) of the prototype S protein of SARS-COV2, along with several common variants using bioinformatics tools. We discovered the variability in antigenicity among the mutants, for instance, in the more widespread D614G variant the change of epitope was least affected, only with slight increase of antigenicity. However, the antigenic epitopes of some mutants change greatly. These results could be of potential importance for future vaccine design and application against SARS-CoV2 variants.
Open AccessThe influence of major S protein mutations of SARS-CoV-2 on the potential B cell epitopes
SARS-CoV-2 has rapidly transmitted worldwide and results in the COVID-19 pandemic. Spike glycoprotein on surface is a key factor of viral transmission, and has appeared a lot of variants due to gene mutations, which may influence the viral antigenicity and vaccine efficacy. Here, we used bioinformatic tools to analyze B-cell epitopes of prototype S protein and its 9 common variants. 12 potential linear and 53 discontinuous epitopes of B-cells were predicted from the S protein prototype. Importantly, by comparing the epitope alterations between prototype and variants, we demonstrate that B-cell epitopes and antigenicity of 9 variants appear significantly different alterations. The dominant D614G variant impacts the potential epitope least, only with moderately elevated antigenicity, while the epitopes and antigenicity of some mutants(V483A, V367F, etc.) with small incidence in the population change greatly. These results suggest that the currently developed vaccines should be valid for a majority of SARS-CoV-2 infectors. This study provides a scientific basis for large-scale application of SARS-CoV-2 vaccines and for taking precautions against the probable appearance of antigen escape induced by genetic variation after vaccination. Author Summary: The global pandemic of SARS-CoV-2 has lasted for more than half a year and has not yet been contained. Until now there is no effective treatment for SARS-CoV-2 caused disease (COVID-19). Successful vaccine development seems to be the only hope. However, this novel coronavirus belongs to the RNA virus, there is a high mutation rate in the genome, and these mutations often locate on the Spike proteins of virus, the gripper of the virus entering the cells. Vaccination induce the generation of antibodies, which block Spike protein. However, the Spike protein variants may change the recognition and binding of antibodies and make the vaccine ineffective. In this study, we predict neutralizing antibody recognition sites (B cell epitopes) of the prototype S protein of SARS-COV2, along with several common variants using bioinformatics tools. We discovered the variability in antigenicity among the mutants, for instance, in the more widespread D614G variant the change of epitope was least affected, only with slight increase of antigenicity. However, the antigenic epitopes of some mutants change greatly. These results could be of potential importance for future vaccine design and application against SARS-CoV2 variants.
- Open Access
- 27 February 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (2) , e0229327
HLA class I restricted epitopes prediction of common tumor antigens in white and East Asian populations: Implication on antigen selection for cancer vaccine design
Tumor antigens processed and presented by human leukocyte antigen (HLA) Class I alleles are important targets in tumor immunotherapies. Clinical trials showed that presence of CD8+ T cells specific to tumor associated antigens (TAAs) and tumor neoantigens is one of the main factors resulting in tumor regression. Affinity prediction of tumor antigen epitopes to HLA is an important reference index for peptide selection, which is highly individualized. In this study, we selected 6 CTAs (cancer-testis antigens) commonly used in cancer immunotherapy and top 95 hot mutations from the Cancer Genome Atlas for analyzing potential epitopes with high affinities to the common HLA class I molecules in white and East Asian population, respectively. The results showed that the overall difference in CTAs epitope prediction is small between the two populations. Meanwhile, there is a linear relationship between the CTAs peptide length and the relative overall epitope occurrence. However, the difference is bigger for epitopes prediction of missense mutations between the two populations. It is worth noting that, both in the two populations, the single point mutations with the highest incidences have the lowest epitope occurrences while the mutations with the highest epitope occurrences are with low mutation incidences. This may be the result of long-term selection by the host immunosurveillance. Frameshift/inframe indel mutation neoantigens are between CTAs and spot mutation neoantigens in the relationship between peptide length and predicted epitope number. Our results help provide clues for tumor antigen and epitope selection in cancer vaccine design.
- 27 February 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (2) , e0229327
Open AccessHLA class I restricted epitopes prediction of common tumor antigens in white and East Asian populations: Implication on antigen selection for cancer vaccine design
Tumor antigens processed and presented by human leukocyte antigen (HLA) Class I alleles are important targets in tumor immunotherapies. Clinical trials showed that presence of CD8+ T cells specific to tumor associated antigens (TAAs) and tumor neoantigens is one of the main factors resulting in tumor regression. Affinity prediction of tumor antigen epitopes to HLA is an important reference index for peptide selection, which is highly individualized. In this study, we selected 6 CTAs (cancer-testis antigens) commonly used in cancer immunotherapy and top 95 hot mutations from the Cancer Genome Atlas for analyzing potential epitopes with high affinities to the common HLA class I molecules in white and East Asian population, respectively. The results showed that the overall difference in CTAs epitope prediction is small between the two populations. Meanwhile, there is a linear relationship between the CTAs peptide length and the relative overall epitope occurrence. However, the difference is bigger for epitopes prediction of missense mutations between the two populations. It is worth noting that, both in the two populations, the single point mutations with the highest incidences have the lowest epitope occurrences while the mutations with the highest epitope occurrences are with low mutation incidences. This may be the result of long-term selection by the host immunosurveillance. Frameshift/inframe indel mutation neoantigens are between CTAs and spot mutation neoantigens in the relationship between peptide length and predicted epitope number. Our results help provide clues for tumor antigen and epitope selection in cancer vaccine design.